Keyphrases
Recombinant Activated Factor VII (rFVIIa)
100%
Hemophilia
76%
Bleeding Episodes
50%
Bleeding
46%
Hemophilia B
42%
Intramuscular Hemorrhage
33%
Mucocutaneous Hemorrhage
33%
NovoSeven
33%
Intracranial Hemorrhage
33%
Hemophiliacs
33%
Home Treatment
33%
Blind Comparison
33%
Joint Hemorrhage
33%
Moderate to Severe
33%
Randomized Double-blind
33%
Hemophilia Patients
29%
Hemostasis
27%
Joint Bleeding
17%
Inhibitor Antibodies
16%
Dose number
16%
Mucocutaneous Bleeding
9%
Fibrinogen
9%
Home Setting
9%
Activity Level
9%
Acute Hemarthrosis
8%
% Response
8%
Peripheral muscle
8%
Dosing Regimen
8%
Dosage Regimen
8%
Appropriate Dose
8%
Multicenter Trial
8%
Factor 9
8%
Pharmacology, Toxicology and Pharmaceutical Science
Haemophilia A
77%
Recombinant Blood Clotting Factor 7a
66%
Bleeding
66%
Haemophilia B
44%
Hemarthrosis
41%
Blood Stasis
41%
Blood Clotting Factor 7
38%
Brain Hemorrhage
33%
Ciclonicate
33%
Fibrinogen
33%
Clinical Study
16%
Antifibrinolytic Agent
16%
Fibrin Degradation Product
16%
Epistaxis
16%
Antithrombin III
16%
Muscle Bleeding
16%
Cerebrovascular Accident
16%
Antiplasmin
16%
Plasminogen
16%
Ataxia
16%
Tranexamic Acid
16%
Tissue Factor Pathway Inhibitor
16%
Adverse Event
11%
Blood Clotting Factor 9
8%
Procoagulant
8%
Blood Clotting Factor 8
8%
Thrombophlebitis
5%
